Fragrance or foolery: 15 big drug events will resolve before April
This article was originally published in Scrip
There are 15 big drug development decisions to be taken before April 1, seven of those in the hands of regulatory agencies in the US and Europe. The rest are dependent on clinical data, and some of the companies involved almost certainly already know which way the results going. All of which leaves 14 companies' senior management teams (Sanofi's has two clinical trials to ponder) wondering whether they will feel like bunches of April flowers, or bunches of fools.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.